Loading...
•
Dec 31, 2022
COMPASS Q4 2022 Earnings Report
COMPASS Pathways reported financial results for Q4 2022 with a net loss of $30.9 million.
Key Takeaways
COMPASS Pathways announced its Q4 and year-end 2022 financial results, highlighted by the commencement of its Phase 3 pivotal program for COMP360 psilocybin therapy in treatment-resistant depression. The company reported a net loss for the quarter of $30.9 million, or $0.73 loss per share, and a cash position of $143.2 million as of December 31, 2022.
Phase 3 pivotal program for COMP360 in treatment-resistant depression is underway.
Updates to the Phase 3 program accelerate data readout and streamline long-term follow-up.
Net loss for the quarter was $30.9 million, or $0.73 loss per share.
Cash and cash equivalents were $143.2 million as of December 31, 2022.
Forward Guidance
First quarter 2023 net cash used in operating activities is expected to be in the range of $24 million to $32 million and the full-year 2023 to be in the range of $85 million to $110 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...